How do I install the Endo T Trial Baseline Nonoral skill?

Run npx skillmds@latest add dromlakhani/endo-t-trial-baseline-nonoral in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo T Trial Baseline Nonoral safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo T Trial Baseline Nonoral?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo T Trial Baseline Nonoral free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo T Trial Baseline Nonoral?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo T Trial Baseline Nonoral by dromlakhani

Name: Endo T Trial Baseline Nonoral
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo T Trial Baseline Nonoral

Recommends checking baseline testosterone level and using an approved non-oral preparation (such as transdermal patch, gel, or cream) when initiating a testosterone trial for hypoactive sexual desire disorder (HSDD) in women. Triggered when a clinician plans to start a T trial for HSDD and needs to confirm baseline levels and select an appropriate delivery method.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Suggest baseline testosterone check and approved non-oral formulation for trial

STEP 1 — Gather Information

Confirm HSDD diagnosis per DSM-5, verify postmenopausal status, and screen for contraindications (pregnancy, androgen-sensitive malignancy, uncontrolled hyperandrogenism).
Action: If criteria are met and no contraindications exist, proceed to order baseline testosterone; otherwise, do not initiate a testosterone trial.

STEP 2 — Rule In / Rule Out

Determine feasibility of obtaining baseline testosterone (blood draw possible, laboratory access).
Action: If feasible, order serum total and free testosterone (or total T with SHBG if free unavailable); if not feasible, document the limitation and consider deferring the trial or using alternative assessment.

STEP 3 — Classify or Stratify

Assess local availability of approved non-oral testosterone preparations (transdermal patch, gel, or cream).
Action: If an approved non-oral formulation is available, select it for use; if unavailable, discuss alternatives with the patient or advise against trial initiation due to lack of appropriate product.

STEP 4 — Decide

Initiate the testosterone trial with the chosen non-oral preparation at a physiological dose (e.g., transdermal patch 300 µg daily) and schedule a follow‑up testosterone level measurement in 3–6 weeks to evaluate for overuse or signs of androgen excess.
Action: Start treatment and arrange follow‑up lab and clinical review.

Clinical Guardrails / Mimics / Pitfalls

Do not use oral testosterone formulations (risk of hepatic toxicity, insufficient safety data in women); avoid unmonitored supraphysiologic dosing; discontinue immediately if androgenic adverse effects appear (acne, hirsutism, voice deepening, clitoromegaly); never initiate therapy in pregnancy or lactation; avoid formulations designed for men due to risk of overdose.

Concrete Clinical Example

A 54‑year‑old postmenopausal woman presents with distressing low libido consistent with HSDD. She has no contraindications. Baseline total and free testosterone are ordered. An approved transdermal testosterone patch is available locally. She begins the patch at 300 µg/day and returns in 4 weeks for testosterone level and symptom assessment.

Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260

---name: endo-t-trial-baseline-nonoraldescription: Recommends checking baseline testosterone level and using an approved non-oral preparation (such as transdermal patch, gel, or cream) when initiating a testosterone trial for hypoactive sexual desire disorder (HSDD) in women. Triggered when a clinician plans to start a T trial for HSDD and needs to confirm baseline levels and select an appropriate delivery method.---# Suggest baseline testosterone check and approved non-oral formulation for trial## STEP 1 — Gather InformationConfirm HSDD diagnosis per DSM-5, verify postmenopausal status, and screen for contraindications (pregnancy, androgen-sensitive malignancy, uncontrolled hyperandrogenism). **Action:** If criteria are met and no contraindications exist, proceed to order baseline testosterone; otherwise, do not initiate a testosterone trial.## STEP 2 — Rule In / Rule OutDetermine feasibility of obtaining baseline testosterone (blood draw possible, laboratory access). **Action:** If feasible, order serum total and free testosterone (or total T with SHBG if free unavailable); if not feasible, document the limitation and consider deferring the trial or using alternative assessment.## STEP 3 — Classify or StratifyAssess local availability of approved non-oral testosterone preparations (transdermal patch, gel, or cream). **Action:** If an approved non-oral formulation is available, select it for use; if unavailable, discuss alternatives with the patient or advise against trial initiation due to lack of appropriate product.## STEP 4 — DecideInitiate the testosterone trial with the chosen non-oral preparation at a physiological dose (e.g., transdermal patch 300 µg daily) and schedule a follow‑up testosterone level measurement in 3–6 weeks to evaluate for overuse or signs of androgen excess. **Action:** Start treatment and arrange follow‑up lab and clinical review.## Clinical Guardrails / Mimics / PitfallsDo not use oral testosterone formulations (risk of hepatic toxicity, insufficient safety data in women); avoid unmonitored supraphysiologic dosing; discontinue immediately if androgenic adverse effects appear (acne, hirsutism, voice deepening, clitoromegaly); never initiate therapy in pregnancy or lactation; avoid formulations designed for men due to risk of overdose.## Concrete Clinical ExampleA 54‑year‑old postmenopausal woman presents with distressing low libido consistent with HSDD. She has no contraindications. Baseline total and free testosterone are ordered. An approved transdermal testosterone patch is available locally. She begins the patch at 300 µg/day and returns in 4 weeks for testosterone level and symptom assessment.**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260

Frequently asked questions